Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.

Ring, J.; Worm, M.; Wollenberg, A.; Thyssen, J.P.; Jakob, T.; Klimek, L.; Bangert, C.; Barbarot, S.; Bieber, T.; de Bruin-Weller, M.S.; Chernyshov, P.V.; Christen-Zaech, S.; Cork, M.; Darsow, U.; Flohr, C.; Fölster-Holst, R.; Gelmetti, C.; Gieler, U.; Gutermuth, J.; Heratizadeh, A.; Hijnen, D.J.; von Kobyletzki, L.B.; Kunz, B.; Paul, C.; De Raeve, L.; Seneschal, J.; Simon, D.; Spuls, P.I.; Stalder, J.F.; Svensson, A.; Szalai, Z.; Taieb, A.; Torrelo, A.; Trzeciak, M.; Vestergaard, C.; Werfel, T.; Weidinger, S.; Deleuran, M.

doi:10.1111/jdv.17237

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.

Détails

Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Tous droits réservés

ID Serval

serval:BIB_A3E713D81992

Type

Article: article d'un périodique ou d'un magazine.

Sous-type

Lettre (letter): communication adressée à l'éditeur.

Collection

Publications

Institution

UNIL/CHUV

Titre

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.

Périodique

Journal of the European Academy of Dermatology and Venereology

Auteur⸱e⸱s

Ring J., Worm M., Wollenberg A., Thyssen J.P., Jakob T., Klimek L., Bangert C., Barbarot S., Bieber T., de Bruin-Weller M.S., Chernyshov P.V., Christen-Zaech S., Cork M., Darsow U., Flohr C., Fölster-Holst R., Gelmetti C., Gieler U., Gutermuth J., Heratizadeh A., Hijnen D.J., von Kobyletzki L.B., Kunz B., Paul C., De Raeve L., Seneschal J., Simon D., Spuls P.I., Stalder J.F., Svensson A., Szalai Z., Taieb A., Torrelo A., Trzeciak M., Vestergaard C., Werfel T., Weidinger S., Deleuran M.

ISSN

1468-3083 (Electronic)

ISSN-L

0926-9959

Statut éditorial

Publié

Date de publication

06/2021

Peer-reviewed

Oui

Volume

Numéro

Pages

e362-e365

Langue

anglais

Notes

Publication types: Letter
Publication Status: ppublish

Résumé

Since the introduction of active vaccination against SARS-CoV-2 infection, there has been a debate about the risk of developing severe allergic or anaphylactic reactions among individuals with a history of allergy. Indeed, rare cases of severe allergic reactions have been reported in the United Kingdom and North America. By february 2021 a rate of 4,5 severe allergic reactions occurred among 1 million patients vaccinated with the mRNA-based COVID-19 vaccines, which is higher than the generally expected rate of severe allergic reactions to vaccinations of around 1 in 1 million.

Mots-clé

Anaphylaxis, COVID-19, COVID-19 Vaccines, Dermatitis, Atopic/prevention & control, Humans, SARS-CoV-2, Vaccines

URN

urn:nbn:ch:serval-BIB_A3E713D819921

OAI-PMH

oai:serval.unil.ch:BIB_A3E713D81992

DOI

10.1111/jdv.17237

Pubmed

33752263

Web of science

000636288200001